Regional-specific calibration enables application of bioinformatic evidence for clinical
classification of 5' cis-regulatory variants in Mendelian disease

Rehan M. Villani[1], Maddison E. McKenzie[1], Aimee L. Davidson[1], Amanda B. Spurdle[1,2]

1 Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia

2 University of Queensland, Brisbane Australia

Abstract

To date, clinical genetic testing and approaches to classify genetic variants in Mendelian disease genes
have focused heavily on exonic coding and intronic gene regions. This multi-step study was undertaken
to provide an evidence base for selecting and applying bioinformatic approaches for use in clinical
classification of 5' cis-regulatory region variants. Curated datasets of rare clinically reported disease-
causing 5' cis-regulatory region variants, and variants from matched genomic regions in population
controls, were used to calibrate six bioinformatic tools as predictors of variant pathogenicity.
Likelihood ratio estimates were aligned to code weights following ClinGen recommendations for
application of the American College of Medical Genetics (ACMG)/American Society of Molecular
Pathology (AMP) classification scheme. Considering code assignment across all reference dataset
variants, performance was best for CADD (81.2%) and REMM (81.5%). Optimized thresholds provided
moderate evidence towards pathogenicity (CADD, REMM), and moderate (CADD) or supporting
(REMM) evidence against pathogenicity. Both sensitivity and specificity of prediction were improved
when further categorizing variants based on location in an EPDnew-defined promoter region.
Combining predictions (CADD, REMM, and location in a promoter region) increased specificity at the
expense of sensitivity. Importantly, the optimal CADD thresholds for assigning ACMG/AMP codes PP3
(≥10) and BP4 (≤8) were vastly different to recommendations for protein-coding variants (PP3 ≥ 25.3;
BP4 ≤22.7); CADD <22.7 would incorrectly assign BP4 for >90% of reported disease-causing cis-
regulatory region variants. Our results demonstrate the need to consider a tiered approach and
tailored score thresholds to optimize bioinformatic impact prediction for clinical classification of cis-
regulatory region variants.

Keywords: ACMG/AMP, non-coding, cis-regulatory, promoter, variant classification, genomic variant,
genome, humans, mutation, sequence analysis, DNA, genetic testing, genetics, human genetics

Introduction

Advances in genomic sequencing technology have led to dramatic improvements in diagnostic rates for inherited disease. Fundamental to these developments were the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) recommendations for clinical interpretation of genomic variants, which provided guidelines for classifying a given variant's potential role in disease [1]. To date, the overwhelming majority of variants classified as disease-causing are located in the protein-coding region of the genome [2]. The non-coding region, despite representing approximately 98% of the genome, remains largely unexplored as an explanation for Mendelian disease.

The non-coding sequence upstream of protein-coding genes, known as the cis-regulatory region, has important regulatory functions [3]. Variants in non-coding regions with known or suspected cis-regulatory function are thus high priority for investigating potential impact on gene function and disease predisposition.

Cis-regulatory regions contain a number of different functional domains (Figure 1), typically including: a core promoter which enables gene transcriptional output; a proximal promoter; and an upstream untranslated region (5' UTR). Further, the 5' UTR may contain introns that modulate gene output e.g. expression level, spatial or temporal modifications. Within these domains are identifiable cis-regulatory sequence motifs. The cis-regulatory region domains can contain: promoter motifs required for transcription initiation such as a TATA box; downstream promoter element (DPE); initiator element (Inr); or motif ten element (MTE) [4-6]. Additionally, domains such as CpG islands, CCAAT regions, regions of open chromatin and various epigenetic markers, can convey regulatory function and are enriched in promoter regions [7-11]. Finally, a diverse range of transcription factor binding motifs enable temporal and spatial gene modulation [12]. The variable composition of domains and motifs in the cis-regulatory region upstream of a gene dictate its expression and behavior. Thus, while not directly encoding protein sequence, the cis-regulatory regions proximal to the protein-coding gene sequence are crucial for normal biological function.

Figure 1. Overview of features associated with cis-regulatory regions.
Promoter regions contain a variety of motifs, with substantial diversity in features present and relative locations of motifs between genes. The cis-regulatory region includes the main regulatory regions upstream (5') to the translation start site (TSS), including the core and proximal promoter/s, and encompassing any untranslated regulatory introns and exons, and the transcription initiation site (TIS). The functional components of the core promoter may include a Beta recognition element (BRE), a TATA box or variation thereof (TATA), an initiator sequence (termed Inr), and/or a downstream promoter

element (DPE). These sequence features are generally observed within -40 bp to +40 bp of the TSS (+1
position within the Inr). The cis-regulatory region also contains a variety of transcription modulating
regions, including CCAATT box sites and transcription factor binding sites (TFBs) which regulate
temporal and spatial control of gene expression. Not represented in this image are a number of
additional cis-regulatory elements, including the E box, X box and GC sites. Cis-regulatory elements are
observed in various combinations, sometimes with multiple instances of a functional element, and
also are not all found concurrently.

Variants in cis-regulatory regions cause inherited disease through impacting gene function, generally
via altering gene regulation. Disease-causing variants have been observed across the range of cis-
regulatory motifs, and these variants have generally been reported to cause phenotypes similar to
pathogenic variants within the associated protein-coding regions [13]. Some previously reported
examples include: variants upstream of *PTEN* that reduce promoter activation causing Cowden
syndrome [14]; variants in the TATA box recognition sites of *HBB* and *HBD* that alter transcription
initiation by TATA Binding Protein and are reported as causal for β- and δ-thalassemia [15]; deletions
upstream of the TSS in the *APC* gene promoters 1A or 1B identified as causal for Familial Adenoma
Polyposis [16]; and variants in the 5' UTR of *MLH1* that reduce transcription that have been reported to
cause hereditary non-polyposis colorectal cancer (also known as Lynch Syndrome) [17]. Despite such
examples establishing precedence, cis-regulatory region variants are not routinely examined in the
clinical diagnostic setting [2].
86
Ellingford et al. [2] recently published recommendations to support the interpretation of non-coding
variants in alignment with the ACMG/AMP variant classification guidelines [1]. These recommendations
included a general description regarding use of bioinformatic prediction tools for non-coding variant
interpretation, with reference to several tools that might be used to predict variant impact on splicing,
or deleteriousness of other categories of non-coding region variants. The authors specifically
highlighted the importance of accurately annotated true positive pathogenic variants for training, and
cautioned against over-interpretation of output from genome-wide predictors.
94
Another important consideration for regulatory region variant effect prediction is how to prioritize,
compare and select bioinformatic tool/s for both calibration and ongoing use. There are numerous
tools with potential relevance for impact prediction of non-coding variants (see Table S1 for examples).
For ease of application in a variant curation setting, ideally bioinformatics tool/s should be: current
and maintained; easy to use (if possible, even for those without coding skills); publicly available
without cost; and capable of batch variant annotation. While many previous studies have compared
tool performance in the process of assessing a new bioinformatic tool for non-coding regions, we
identified relatively few apparently impartial reviews of computational tools that predict impact on
function for non-coding variants [2, 18-25]. Of the latter, only one study [24] identified optimal thresholds
for predicting impact of non-coding variants, and reported tool sensitivity and specificity using these
thresholds. While sensitivity and specificity are key factors in selecting which tool/s may be used to
predict variant pathogenicity, formal calibration of a tool using known pathogenic and benign variants
is required to determine the appropriate evidence weight for application in clinical variant
classification [26]. Bayesian modelling of the ACMG/AMP variant classification guidelines has provided
a framework on how to assign evidence weights based on likelihood ratio (LR) towards pathogenicity
[27]. Recently, a ClinGen computational subgroup (Pejavar et al. 2022) used this approach to define
score thresholds for bioinformatic prediction evidence weighting for missense variants [28]. In this study,
only four of the 13 tools assessed were potentially applicable for non-coding variants: two
conservation/constraint scores (GERP and PhyloP) and two meta-predictors (CADD and BayesDel) [29-
32]. Given that the mechanisms underlying cis-regulatory region function are quite different to those
for protein-coding regions, we hypothesized that the score thresholds and evidence weights derived
for missense variant impact cannot be assumed to be applicable for cis-regulatory region variants.

We applied multiple quality control and filtering steps to publicly accessible information to generate
refined reference datasets of reported disease-causing variants (representing pathogenic variants) and
region-matched control variants, exclusively located in cis-regulatory regions. These reference datasets
were used to compare performance of, and evaluate evidence weight for, scores from six bioinformatic
prediction tools and promoter region annotation. The results from this calibration study demonstrate
the need to consider a tiered approach with tailored score thresholds to optimize impact prediction
for clinical classification of cis-regulatory region variants.

Methods

Scoping analyses relating to variant effect and location in non-coding regions

A preliminary dataset of non-coding variants was sourced from ncVarDB [20], and annotated using VEP
(online GUI version 109, 28 March 2023) to obtain the Ensembl molecular consequence and CADD
PHRED scores (v1.6). CADD score profiles for benign and pathogenic variants, categorized as defined
by ncVarDB, were compared using a density plot. Non-coding variants were then grouped by Ensembl
molecular consequence, with splicing-related molecular consequences were collapsed into a single
'splicing' group, and variants with no molecular consequence annotated were collapsed into a single
group 'other'. The CADD PHRED score of benign and pathogenic variants was compared for each
molecular consequence group using bar graph visualization.

Sourcing reported disease-causing cis-regulatory variants

Source data included large-scale studies and variant databases [20, 33-35], and smaller research
publications (published up to February 2023) reporting Mendelian disease-causing regulatory region
variants identified in the clinical setting (clinically reported and/or patient-identified). Variants that
were annotated by the original source as 5' UTR, upstream or regulatory region variants were selected
to generate a combined dataset of 962 variant records (Table S2). 2 variants
(NC_000001.11:g.11023351G>A, NC_000014.9:g.75958692G>A) were excluded based on literature
reporting their location as 3' UTR (though the original source annotation as 5'UTR).

These reported disease-causing variants (hereafter also referred to as disease variants) were
investigated for literature and functional evidence via the following approaches: ClinVar (collected
November 2022)[36]; dbSNP; LitVar search using rsID and/or variant location; and Google search (online
search completed 6 December 2022) for variant MANE transcript associations, HGVS
nomenclature/dbSNP identifiers, gene and alternate gene references, and promoter-related
information. PMIDs were recorded for all publications that appeared to capture evidence specific to
the variant (Table S3). After removal of duplicates, 576 unique cis-regulatory region variants remained.

Identifying cis-regulatory regions of interest, 5kb upstream regions of MANE transcripts

The translation and transcription start sites for all MANE_Select and MANE_Plus_Clinical transcripts
were collected using BioMart (Ensembl) [37]. The region start was determined as genomic location 5kb
upstream of the transcription start site for the positive strand or 5kb downstream of the transcription
start site for the negative strand. The last nucleotide 5' to the translation start site in positive strand
or first nucleotide 3' to the translation start site in the negative strand was designated the region end
location. A 'region of interest' input BED file [38] was then created to match the relevant genes for the
cis-regulatory reported disease variants.

Population variant frequency/conservation correlation

Variants located within the regions of interest (MANE genes) were selected from gnomAD v3.0 VCF
files [39]. Maximum population allele frequency (maxAF) was calculated for 314,817 variants by
selecting variants based on the highest alternative AF from (non-founder) populations (Non-Finnish
European, South-Asian, African-American/African ancestry, Latino, East Asian). Precomputed GERP
(version homo_sapiens GRCh38, downloaded 02 February 2023) and phyloP 100V GRCh38 vertebrate

(version hg38.100way.phyloP100way 2015-05-11, downloaded 02 February 2023) scores were
sourced from UCSC and gnomAD variants annotated with precomputed scores via VEP (See
Supplementary Methods). GERP and phyloP 100V scores were obtained for single nucleotide variants
only. The correlation between maxAF and GERP, and maxAF and phyloP 100V, was investigated via
scatterplot with linear regression and Spearman's correlation coefficient.

gnomAD variants were binned into seven groups by maxAF: [1] 0 -0.00001, [2] >0.00001-0.00002,
[3] >0.00002-0.0001, [4] >0.0001-0.001, [5] >0.001-0.01, [6] >0.01-0.1, and [7] >0.1–1.

Summary statistics of both phyloP 100V (Table S4) and GERP (Table S5) were calculated for each of
these bins, including mean and standard deviation of each maxAF bin.

Based on conservation metrics for the different bins, the maxAF bin [3] >0.00002-0.0001 was used as
source for a presumed benign control variant set. To enable analysis via web-based annotation
platforms (e.g. CADD web annotation recommends limiting to around 10 000 variants), a subset of the
maxAF bin [3] was created by random selection of 10% of the total 127,868 variants. This formed the
initial control variant set comprising 12,788 variants (Table S6), hereafter also referred to as control
variants.

Compilation of reference datasets

To select refined reference datasets of cis-regulatory region variants for calibrating bioinformatic tools,
the 576 reported disease-causing variants (Table S3) and 12,788 control variants (gnomAD population
variants with maxAF >0.00002-0.0001) (Table S6) were filtered to remove variants with potential to
confound the analysis. Variants were excluded from the reference datasets if they: were predicted to
alter an amino acid in any transcript; overlapped with the coding region of the MANE transcript
(including introns between coding exons); were predicted to alter splicing by max SpliceAI delta score
≥0.2 (of which a subset had published evidence for impact on splicing, Table S7); had VEP-annotated
ClinVar classification in opposition with the reference dataset grouping (i.e. disease variants with a
benign classification or control variants with a pathogenic classification); were GWAS-identified with
experimental evidence supporting causality for common disease [40]; or had ambiguity concerning their
role in disease from a broad literature search (e.g. some variants were reported *in cis* with a second
potentially causal variant). Annotations relating to all variant exclusions are shown in Table S8, and
detailed description of variant exclusion methods is provided in the Supplemental methods.

Selection of bioinformatic impact prediction tools

193 A literature search identified 269 bioinformatic tools with potential application for non-coding variant
194 classification (Table S1). To prioritize tools for further clinical evaluation and calibration, we selected a
195 subset of six tools previously evaluated as highly performing in Wang et al. 2022. In addition, the
196 EPDnew database of promoter regions (version H. sapiens 006, GRCh38) [41] was selected as a source
197 of experimental and computationally derived promoter locations.

Bioinformatic tool score collection and variant annotation

Variant annotations from multiple sources were combined in R (version 4.2.3), further information on
tools and datasets can be found in Supplemental Methods and Table S9, and a full collation of
reference dataset variant annotations can be found in Table S10.

In summary, the annotations were as follows. VEP (online GUI version 109, 28 March 2023) was used
to source RefSeq transcripts, consequence (from Ensembl), MANE_Select, MANE_Plus_Clinical, Amino
Acids, CLIN_SIG (ClinVar classification) annotations. Custom VEP command line version 99.2 [42] was
used to collect GERP, vertebrate phyloP 100V, LINSIGHT, and Eigen annotations. CADD (v1.6), FATHMM-
MKL, FATHMM-XF and REMM (V0.4) annotations were obtained via web GUI. In addition, promoter-
associated "sub"-annotations were extracted from the CADD results table (web GUI sourced), including;
CpG, percent CpG in a window of +/- 75bp (default: 0.02); GC percent, percent GC in a window of +/-

75bp (default: 0.42); RemapOverlapTF, Regulatory region map number of different transcription
factors binding (default: - 0.5); and Encode Regulatory Region Feature annotations. Control and disease
variant scores were compared, using default CADD score settings. For Encode regulatory features,
regulatory feature overlap categories were lumped to calculate the dataset proportion overlap with
any regulatory feature. Splicing prediction analysis was performed using SpliceAI [43]. Based on
calibration results reported previously [44], maximum delta score of ≥ 0.2 was considered as
bioinformatic evidence for predicted impact on splicing. Annotation of variant location within a
promoter region was extracted via locational overlap with EPDnew (version H. sapiens 006, GRCh38)
using the R GenomicRanges (version 1.50.2).

All annotations were performed on GRCh38, except LINSIGHT and FATHMM-MKL, for which variant
GRCh37 positions were determined using web-based UCSC LiftOver tool, annotations collected using
GRCh37 positions and returned to the corresponding GRCh38 locations.

221　Statistics and bioinformatic tool calibration

Figures were generated in R (version 4.2.3)/R Studio (2023.06.01), Microsoft excel and/or Inkscape
(0.92). Statistical analyses were performed using R/R Studio, including linear regression, Spearman's
correlation, Wilcoxon rank sum tests, Chi-Square tests and summary statistics.

The overall bioinformatic tool evaluation was performed by: (i) allocating score categories; (ii)
calculating the score category LR and resulting evidence category/strength; (iii) evaluating the
combined performance of the categories. An online LR calculation tool developed and applied for
calibration of splicing prediction tool thresholds [44] was used to determine the area under the curve
(AUC), Youden's index and the score threshold corresponding to the Youden's index. Upper and lower
thresholds defining score categories were determined using the score defined by Youden's index to
designate the central point for an uncertain zone comprised of approximately 10% of variants.
Sensitivity, specificity and accuracy of the scored variants were determined based on the defined score
categories. LRs were estimated for the different bioinformatic score categories by comparison of the
proportions observed for control and reported disease-causing variants, as described previously [45].
ACMG/AMP criteria weights were assigned based on LR, following published LR range/threshold
recommendations [27].

The evaluation of selected bioinformatics impact predictor tools was then adjusted to include all
variants (including unscored and uninformative variants combined, referred to as the undetermined
group), with these whole reference set evaluation results designated as the clinical performance. For
clinical performance comparisons, the overall score category alignment with the reference set
experimental group was determined as correct, incorrect and undetermined. Correct referred to the
variant scoring in a category providing at least supporting evidence consistent with the reference set
status, either towards pathogenicity for disease variants (true positive) or against pathogenicity for
control variants (true negative). Incorrect referred to the variant scoring in a category providing
evidence inconsistent with reference set status, either against pathogenicity for disease variants (false
negative) or towards pathogenicity for control variants (false positive). Undetermined referred to both
any variant that did not score (no score) and/or variants for which the respective tool did not reach an
LR corresponding to at least supporting evidence either towards or against pathogenicity
(uninformative).

250　Results

251　Non-coding variants have distinct impact prediction score profiles

252　Non-coding regions contain motifs with a variety of functions, therefore it should be anticipated that
253　non-coding variants can cause impact on gene expression/function via a broad set of mechanisms. We
254　hypothesized that this may present as large variability in variant impact prediction scores depending
255　on specific non-coding region features, with implications for selection of appropriate thresholds for

assigning evidence towards or against pathogenicity. The bioinformatic prediction tool CADD was selected for preliminary analysis based on its common use as a variant impact predictor in clinical settings [28], and CADD (CADD_PHRED) scores for different Ensembl variant consequence categories were compared for variants in the publicly accessible dataset of non-coding variants ncVarDB [20, 31]. Variants in different locational-based consequence categories showed different CADD score profiles (Figure 2), indicating need to consider non-coding variant location category when calibrating bioinformatic tools for predicting clinical impact for this broad group of variants.

Figure 2. *CADD scores of ncVarDB variants separated by Ensembl consequence category.*
A) Density plot of CADD scores (CADD PHRED) for ncVarDB variants, comparing benign (Ben; n=7228) and pathogenic (Path; n=721) variants. Categorization as benign or pathogenic is as per ncVarDB. Vertical lines indicate missense variant thresholds [28], BP4 indicates the category in which variants would meet at least supporting level of evidence for benignity and PP3 indicating the category in which variants would meet at least supporting level of evidence for pathogenicity according to the missense calibrated thresholds [28]. B) CADD scores median (box center line), 25th and 75th percentiles (upper and lower box boundaries respectively), the inter-quartile range (whisker line), with outlier points plotted individually (dots) comparing benign and pathogenic variants, separated by Ensembl consequence; 'splicing' includes grouped splicing type consequences, and 'other' includes those variants that did not annotate with a molecular consequence. The number of variants is indicated above each group.

Our subsequent analysis focused on the cis-regulatory region of the genome, since it is a relatively well-studied non-coding region with a number of recognizable motifs. For the purposes of this study, the cis-regulatory region was defined as the 5kb sequence upstream of the translation start site to the transcription start site (the nucleotide 5' to the ATG start site). This region spans the 5' UTR, any untranslated introns, the core promoter and the proximal promoter, and is an area generally understood to regulate transcription of the neighboring gene (and would include the 5' UTR and upstream gene region as defined in the ncVarDB [20]).

Identifying a set of disease-causing cis-regulatory region variants

We collated a set of 576 unique variants located in a cis-regulatory region, as defined by their source dataset, and reported as Mendelian disease-causing (see Methods, Table S3). The variant list included mostly single nucleotide variants (SNVs) (536, 92%), but also other small insertion/deletion variants (44, 7.6%), including insertion, deletion and small multi-substitution variants. These 576 variants were located in the cis-regulatory region of 317 genes (or 1523 RefSeq transcripts), meaning some variants

were in proximity to, and therefore potentially functionally relevant for, multiple genes and/or
transcripts. We then: (i) selected the clinically relevant gene, the gene reported to be causal for the
clinically reported condition; (ii) identified the MANE transcript for that gene; and (iii) selected the
variant annotations relevant to this MANE transcript. For 14 variants where a MANE transcript was not
available, the relevant transcript was identified based on the original clinical report of the variant
(identified via publication, or ClinVar submission). When considering the clinically relevant gene and
transcript, the 576 variants annotated to 193 genes. The revised gene and transcript-based annotation
identified a range of Ensembl consequences across the 576 reported disease cis-regulatory variants,
including 231 5' UTR variants, 310 upstream gene variants and 11 intron variants but also 15 splicing
variants, one stop-gained variant, one start-lost, five frameshift and two missense variants (Figure S1).
This observation raises the importance of considering multiple alternative mechanisms for the impact
of potential "regulatory region" variants, and also highlights the need to ensure calibrations are
performed on a verified set of solely cis-regulatory region variants.

In cis-regulatory regions, population maximum allele frequency correlates with conservation

Variant observation and frequency in large population datasets, such as gnomAD, is used to inform
variant pathogenicity [46]. Following the ACMG/AMP classification guidelines, absence from gnomAD is
considered evidence for pathogenicity (code PM2), while presence in gnomAD at a frequency higher
than expected for disease prevalence provides evidence against pathogenicity (codes BA1, BS1) [1].
Previous studies have used variants with high population allele frequency (e.g. a population frequency
greater than 5%) as presumed benign controls for bioinformatic tool development and evaluation [20,
34]. We hypothesized that high variant frequency will correlate with lower conservation, and since
conservation is a key component of many bioinformatic prediction tools, selecting very common
variants as controls could potentially confound tool calibration.

Analysis of gnomAD variants located within the cis-regulatory regions of interest (i.e. matched to those
for the reported disease variants) showed an inverse correlation between maxAF and conservation
score (Figure 3). Evidence for the negative correlation remained after grouping variants into seven
maxAF bins, with lower conservation scores for variants observed when maxAF>0.0001 (Figure 3).
Based on this information, variants with a gnomAD maxAF of >0.00002 to $\leqslant$ 0.0001 were considered
suitable for inclusion as a control group, as this bin showed minimal conservation skewing but
importantly remained within maxAF levels defined as evidence against pathogenicity from the ClinGen
ENIGMA *BRCA1* and *BRCA2* Variant Curation Expert Panel VCEP (See CSpecs,
https://clinicalgenome.org/affiliation/50087/; BS1 _Supporting may be applied for MAF >0.00002 to
$\leqslant$ 0.0001).

Figure 3. Correlation of population allele frequency with conservation scores.

The maxAF for 314,817 single nucleotide variants across 193 cis-regulatory gene regions was selected from non-founder gnomAD populations and binned into maxAF groups. (A) Correlation scatterplot comparing maxAF to phyloP 100V. Spearman's rank correlation coefficients were determined as rho-value -0.05492315, S = 3.9247e+15, p-value < 2.2e-16. (B) Correlation scatterplot comparing maxAF to GERP scores. Spearman's rank correlation coefficients were determined as rho value -0.01679457, S = 4.0028e+15, p-value < 2.2e-16. MaxAF was then grouped into the following maxAF bins: [1] 0 -0.00001, [2] >0.00001-0.00002, [3] >0.00002-0.0001, [4] >0.0001-0.001, [5] >0.001-0.01, [6] >0.01-0.1, and [7] >0.1 − 1. Conservation measures were compared for variants in different maxAF bins, using (C) mean phyloP 100V scores (line indicates 25-75% IQR) and (D) mean GERP scores (line indicates 25-75% IQR)). The number of values per bin, and other summary characteristics, are indicated in Table S4 (phyloP 100V) and Table S5 (GERP).

Selection of reference variants for tool calibration

To select reference datasets of cis-regulatory region variants for calibrating bioinformatic tools, the 576 reported disease variants (Table S3) and 12,788 control variants (gnomAD population variants with maxAF >0.00002-0.0001) (Table S4) were combined and filtered to remove variants with potential to confound the analysis. A substantial proportion of variants were excluded after applying filters: 1221/13,364 (or 9.14%) were located between the transcriptional start and transcriptional end of a MANE transcript (including introns between coding exons); 210/13,364 or 1.57%) were predicted to alter an amino acid (when considering any protein-coding transcripts); 52 variants, 26 each disease

and control, were predicted to alter splicing by max SpliceAI score ≥0.2, of which 18 disease variants
had published evidence for impact on splicing (Table S7); 26 disease variants had a maxAF >0.01 and
would be considered too common to be disease-causing; 61 variants had a reported ClinVar
classification in opposition with the reference dataset grouping (53/576 or 9.20% of disease variants
and 8/12,788 or 0.06% of control variants); one GWAS-identified variant had experimental evidence
supporting it as functionally causal for common disease [40]; and a broad literature search identified
another 19 variants where manual review identified ambiguity in disease causality (see Methods).
Details relating to all variant exclusions are shown in Table S8 and Supplemental Methods.

As summarized in Table 1, after application of these filters a combined cis-regulatory region reference
dataset consisting of 445 reported disease variants (representing "pathogenic" reference variants) and
9,505 control variants (representing "benign" reference variants) was compiled. This combined cis-
regulatory region reference dataset included 8,872 SNVs and 1,078 indels.

Table 1. Filters applied to select reference datasets.

	Reported disease-causing variants	gnomAD control variants
STARTING set[1]	**576**	**12,788**
Coding regions (between start and end of MANE transcript)	47	1,174
Coding (amino acid annotation, any transcript)	35	175
Disease-associated identified by GWAS [40]	1	-
Clinical association unclear in literature	19	-
gnomAD maxAF >0.01	26	-
Reported disease variants with ClinVar benign classification	53	-
Control variants with ClinVar pathogenic classification	-	8
Predicted spliceogenic variants (SpliceAI max delta ≥ 0.2)	26	26
Additional control variants excluded based on location in regions associated with excluded reported disease variants	-	2,650
FINAL refined reference dataset	**445**	**9,505**

358 [1] Some variants met more than one criterion for exclusion.

Calibration of bioinformatic tools for predicting pathogenicity of cis-regulatory region variants

We selected six variant impact prediction score tools for calibration, based on their relatively high
evaluation performance in Wang 2022, CADD, REMM, FATHMM-MKL, FATHMM-XF, Eigen and LINSIGHT
[24, 31, 35, 47-50]. The distribution of prediction scores differed between control and reported disease
variants for all six bioinformatic tools analyzed (Figure 4). To determine the clinical utility of the impact
prediction scores for variant curation against ACMG/AMP recommendations for evidence weighting,
we calibrated each of these six tools using the cis-regulatory region variant reference datasets. Variant
scores were categorized into three groups based on an optimal score threshold as defined by the
Youden's index, an upper and lower threshold were then designated to capture an intermediate,
uninformative group of approximately 10% of the variants (Table 2). Distribution of score ranges for
the reference datasets and the determined thresholds for each bioinformatic prediction score are
shown in Figure 4.

Considering the calibrated score categories of successfully scored variants only, all of the tools showed
sensitivity above 74% and specificity above 67%. Accuracy was highest for FATHMM-MKL (87.28%,
7,738/8,866) and FATHMM-XF (88.33 %, 7,309/8,275) compared to REMM (81.47%, 8,106/9,950) and
CADD (81.22%, 8,081/9,949) (Table 2). However, there was a relatively large proportion of unscored
variants for FATHMM-MKL (10.89%), FATHMM-XF (16.88%) and Eigen (19.84%) which do not score
indels (Table 2), and an extremely high number of unscored variants for LINSIGHT (86.11%) which relies
on dbSNP ID for annotation (and not genomic location/allele).

To evaluate bioinformatic tool performance consistent with application in a clinical diagnostic setting,
sensitivity, specificity and accuracy were adjusted against a baseline of all reference set variants
(scored and unscored). This evaluation revealed highest clinical accuracy for CADD (81.22%,
8,081/9,950 variants) and REMM (81.47%, 8,106/9,950) (Table 2). To determine the strength of
evidence provided by the calibrated score categories, the likelihood ratio (LR) associated with each
score category was then calculated (Table 2). LRs estimated for the optimal score category groups are
shown graphically in Figure 4. The LRs indicate that all six tools can be used to provide at least
supporting evidence towards and against pathogenicity for cis-regulatory region variants. Evidence
towards pathogenicity reached moderate level (LR > 4.3) for CADD, FATHMM-MKL, FATHMM-XF, Eigen
and REMM, and supporting level (LR > 2.08) for LINSIGHT (Table 2). Evidence against pathogenicity
reached moderate level (LR <0.23) for CADD, Eigen, FATHMM-MKL and LINSIGHT, and supporting level
(LR < 0.48) for REMM and FATHMM-XF (Table 2).

Table 2. Bioinformatic tool performance and calibration using optimal thresholds.

	CADD	REMM	FATHMM MKL	FATHMM XF	Eigen	LINSIGHT
# scored variants	9949	9950	8866	8275	7975	1399
# control	9504	9505	8452	7929	7632	1154
# disease	445	445	413	340	343	227
# unscored	1	0	1084	1680	1974	8568
AUC	0.88	0.87	0.91	0.90	0.9	0.82
Youden's Index	0.643	0.612	0.646	0.637	0.714	0.514
Threshold	8.93	0.83	0.50	0.13	0.49	0.21
Lower threshold	8.00	0.80	0.39	0.12	0.394	0.16
Upper threshold	10.00	0.86	0.59	0.14	0.594	0.24
Sensitivity (% scored variants)	80.72	74.94	78.84	74.40	91.08	86.19
Specificity (% scored variants)	87.40	88.28	91.51	91.33	82.43	67.58
Accuracy (% scored variants)	81.22	81.47	87.28	88.33	78.43	64.05
Unscored (%)	0.01	0.00	10.89	16.88	19.84	86.11
Uninformative (%)	6.74	7.09	3.56	2.06	4.23	1.14
Undetermined (%)[1]	6.75	7.09	14.45	18.94	24.07	87.25
LR negative[2]	0.22	0.29	0.23	0.28	0.11	0.21
95% CI low (LR negative)	0.18	0.24	0.19	0.23	0.08	0.15
95% CI high (LR negative)	0.27	0.34	0.28	0.34	0.15	0.29
LR (uninformative)[2]	1.00	0.82	0.97	0.95	0.99	0.90
95% CI low (uninformative)	0.70	0.56	0.59	0.47	0.63	0.55
95% CI high (uninformative)	1.42	1.20	1.58	1.90	1.57	1.48
LR positive[2]	6.41	6.49	9.30	8.60	5.19	2.68
95% CI low (LR positive)	5.25	5.49	7.68	7.15	3.66	1.90
95% CI high (LR positive)	7.81	7.67	11.25	10.34	7.35	3.78
Clinical sensitivity (% all variants)	75.28	70.56	70.34	55.51	66.52	40.67
Clinical specificity (% all variants)	81.49	81.98	78.12	74.30	62.69	7.52
Clinical accuracy (% all variants)	81.22	81.47	77.77	73.46	62.86	9.01

394 [1]Undetermined refers to variants that are both unscored and/or uninformative

395 [2] LR negative refers to LR estimate for bioinformatic score range predicting no impact; LR positive
396 refers to LR estimate for bioinformatic score range predicting impact; LR uninformative refers to LR
397 estimate for the bioinformatic score range for variants in the middle "uninformative" category.

Figure 4. Bioinformatic tool calibration for prediction of cis-regulatory region variant pathogenicity.
The panels on left show the distribution of scores for disease variants compared to the control reference dataset variants, with designated optimal thresholds indicated by lines. The panels on the right show results from bioinformatic tool calibration, with LRs for each of the three optimal categories defined in Table 2, LRpos (LR positive) indicating the LR of the bioinformatic impact score category predicting the variant as disease-causing, LRneg (LR negative) indicating the LR of negatively predicting variant impact, or predicting as a control variant, and LRuninf (LR uninformative) indicates the LR for variants that score between categories. For all LRs, the 95% confidence interval (CI) is indicated by

horizontal lines. Colored vertical lines represent LR boundaries set for evidence strengths as per [27], with evidence strength categories indicated on the graphs. (A,B) CADD. (C,D) REMM. (E,F) FATHMM-MKL. (G,H) FATHMM-XF. (I,J) Eigen. (K,L) LINSIGHT.

Figure 5. Comparison of score prediction categories for the six tools assessed.
Heatmap indicating score categories for (A) control reference dataset variants and (B) disease variants. Blue, score category of variant predicts no impact (against pathogenicity); Red, score category of variant predicts impact (towards pathogenicity); Yellow, score category of variant considered uninformative; Grey, unscored (no score returned). (C) Comparison of overall performance of each tool for the reported disease and control variants combined; correct (blue), referring to percentage of

variants with a score category that aligns with reference dataset group, incorrect (orange), referring
to percentage of variants with a score category in contradiction with reference dataset group, and
undetermined (grey), referring to percentage of variants that were unscored or had scores that did not
reach sufficient strength to provide classification evidence (uninformative). (D) LRs obtained when
considering both CADD and REMM optimal categories combined, the specific score limits of each
combined category indicated. The LR of each combinatorial category are indicated (black dot) with the
95% confidence interval (CI) indicated by horizontal lines. Colored vertical lines represent LR
boundaries set for evidence strengths as per [27], with evidence strength categories indicated on the
graph.

Concordance of score categories between tools was assessed to consider potential value in combining
outputs of different tools for improved performance (Figure 5). This highlighted the absence of scores
returned by LINSIGHT relative to the other tools, for control variants especially (Figure 5A), but also
for reported disease variants (Figure 5B). CADD and REMM showed the highest concordance, while
FATHMM-MKL, FATHMM-XF and Eigen showed a generally similar pattern to CADD and REMM for
scored variants. Since CADD and REMM also showed the highest performance when considering
accuracy for the entire dataset (representing clinical diagnostic application), we investigated if
combining CADD and REMM score categories would improve prediction over use of either tool alone.
As expected, combining categories increased the proportion of variants with an undetermined call,
due to variants with a conflict in category assignment by the two tools (Figure 5C). As shown in Figure
5D, the LR towards pathogenicity for a variant with high CADD and high REMM score category was
increased (LR 10.73) compared to that for either tool alone (CADD LR 6.41, REMM LR 6.49), but
remained within the moderate evidence strength range. Similarly, the LR against pathogenicity was
shifted more clearly into moderate evidence for a variant with low CADD and low REMM category
(CADD/REMM LR 0.20 vs CADD LR 0.22 and REMM LR 0.29, which each alone had met only supporting
level of evidence).

445 Using genomic features to improve disease variant impact prediction

We next assessed if specific genomic features of core-promoter regions differed between reference
dataset disease or control variants, to determine if these features might be useful to improve
prediction accuracy (Figure 6). Reported disease variants showed increased GC percentage, CpG
percentage and TFB overlap, and higher max DNAse hypersensitivity scores. Further, a considerably
higher proportion of reported disease variants (75.7%) overlapped with an Ensembl regulatory feature
(combining annotated regulatory elements from the Ensembl Regulatory Build [51]) compared to
control variants (43.9%). The enrichment of promoter-related features in reported disease versus
control variants highlighted features underlying the bioinformatic tool prediction performance, and
showed the value of considering promoter region overlap for pathogenicity prediction.

Figure 6. Promoter-related components of CADD score are enriched in disease versus control variants. Comparison of promoter-related CADD score component annotations for control variants (n=9,505 scored) and reported disease variants (n=445 scored). A) GC percent averages. B) CpG percent averages (Percent GC in a window of +/- 75bp; default: 0.42). C) REmapOverlapTF average per CADD bin (Remap number of different transcription factors binding; default: - 0.5). D) Encode DNAse Hypersensitivity max score. A) to D) Plots show median (box center line), 25th and 75th percentiles (upper and lower box boundaries respectively), the inter-quartile range (whisker line) with outlier points plotted individually (dots). E) The proportion of the variants in the test group overlapping with an Ensembl Regulatory Feature (all regulatory features combined) for control variants compared to reported disease variants.

Annotation of variant location within a promoter region improves pathogenicity prediction.

As promoter region features were enriched in disease variants compared to controls (see Figure 6), we compared the proportion of control to disease variants located within a promoter region, as defined using the EPDnew promoter prediction database annotation [41]. A significantly greater proportion of reported disease variants (34.8%) were located within EPDnew-defined promoter regions compared to control reference dataset variants (1.8%) (Figure 7). Using EPDnew-region as the definition of promoter location, we calculated that variant location within a promoter region provides moderate evidence towards pathogenicity (LR 19.36, 95% CI 18.08-20.72); location outside of a promoter region did not reach LR thresholds required to provide evidence against pathogenicity (LR 0.66, 95% CI 0.62-0.71).

Based on these findings, we reassessed the evidence strength based on CADD and REMM for the subset of variants outside of the promoter region by recalculating the likelihood ratio for variants outside of EPDnew regions (Figure 7B, 7C). Reassessment showed that the impact prediction tool score thresholds calibrated based on the complete reference dataset remain appropriate for providing evidence towards and against pathogenicity for variants outside of the promoter region. For variants outside of an EPDnew promoter region, LRs for the CADD categories were: ≤8 LR 0.27, 8-10 LR 0.93 (including 7% control, 4% disease variants), ≥10 LR 6.53 (Figure 7C). LRs for the REMM categories were: ≤0.8 LR 0.34, 0.8-0.86 LR 0.73 (including 4% control, 4% disease variants), ≥0.86 LR 6.60 (Figure 7D). Considering CADD and REMM together for variants outside of the promoter region (Figure 7E), overall findings were similar to those for combined CADD and REMM without considering promoter region location (Figure 5). The LRs were further increased if both scores were in the high category or low category compared to using a single scores information, but there was no change in the evidence strength applicable (Table S11). The proportion of incorrect calls decreased to 7.37%, but at the expense of proportion of correct predictions (Figure 7F). Additional details are in Table S12.

Overall these analyses inform a process for variant annotation and bioinformatic categorization, where combining information from EPDnew and impact prediction scores into increasingly defined categories can be applied in cis-regulatory region variant classification. By first determining location in an EPDnew promoter region, followed by annotation of CADD or REMM score for variants outside of the promoter region, the process can provide evidence reaching at least supporting strength for classification of variants located within a cis-regulatory region. This combined two-step process increased the number of variants with a bioinformatic score category applicable, without compromising accuracy. While decreased sensitivity and evidence strengths based on LR estimates do not justify combined use of CADD and REMM, this might nevertheless be considered a more cautious approach in the clinical setting due to improved specificity.

Figure 7. Location within a core-promoter region provides evidence towards variant pathogenicity
A) Proportion of variants located within EPDnew-defined promoter regions. Significantly more
reported disease variants (n= 155/445 34.83%) than control variants (171/9,505, 1.78%) were located
in a promoter region (χ-squared = 1,550.6, df = 1, p-value < 2.2e-16). B) LRs estimated for variants
overlapping EPDnew promoter regions (Epos), compared to variants outside of EPDnew region (Eneg).
C) LRs estimated from CADD score categories outside of EPDnew regions (EPDnew negative regions).
D) LRs estimated from REMM score categories outside of EPDnew regions (EPDnew negative regions).
E) LR estimates of combined CADD and REMM score categories outside of EPDnew regions. (C-E) are
calculated from EPDnew location-negative variants. F) Breakdown of process accuracy for each score
combination showing proportion of correctly called control and disease variants combined (blue),
incorrectly called control and disease variants combined (orange), and variants with undetermined
bioinformatic category, reflecting both variants unscored and for which evidence criteria thresholds
were not met (grey).

Discussion

This multi-step study was undertaken to provide an evidence base for selecting and applying
bioinformatic approaches for use in classification of 5' cis-regulatory region variants, in the context of
Mendelian disease.

Analysis of existing public data highlighted the need to establish tool thresholds according to variant
location and type (inferring likely molecular consequence). Further, our observation that population
control frequency is negatively correlated with conservation scores informed selection of control
reference dataset variants with substantially lower allele frequency. This provided a reference dataset
that was not inherently enriched for lower conservation and thereby lower overall tool scores. An
additional advantage to this approach to control reference dataset collection is that the bioinformatic
calibration process better reflects application in the clinical variant curation setting, where variants are
prioritized for more detailed curation generally after exclusion of common variants that meet
ACMG/AMP population frequency codes. We also demonstrate the need for careful compilation of
reported disease and control variants using various filtering strategies, particularly to ensure that
reference dataset variants are exclusively located in 5' regulatory regions.

Our analyses showed that all six impact prediction tools assessed, when appropriately calibrated using
refined reference sets, could potentially be used to inform regulatory region variant classification
based on the thresholds optimized for this variant type. However, it is critical to consider the
proportion of variants that will scored by a given tool, to measure accuracy in the clinical context. The
extremely high proportion of unscored variants for LINSIGHT (86.11%) would render this tool unusable
in the diagnostic laboratory setting. Although FATHMM-MKL and FATHMM-XF showed the highest
accuracy based on correct predictions for scored variants, they were unable to return scores for indels,
which comprised 11.29% of the full variant reference dataset. When considering all reference dataset
variants, REMM and CADD achieved similar clinical accuracy (CADD 81.22%, REMM 81.47%) and
provided similar strengths of evidence towards and against pathogenicity. Combining CADD and REMM
increased the strength of evidence both towards and against pathogenicity and resulted in fewer
incorrectly assigned evidence categories, but compromised accuracy (fewer variants with correctly
applied evidence). Combining scores therefore represents a cautious approach focused on minimizing
false prediction of impact.

To facilitate the application of bioinformatic annotations for interpretation of 5' cis-regulatory region
variants, we summarize in Figure 8 a staged process by which to consider the potential impact of such
variants. The application of thresholds as derived from our reference datasets is considered
appropriate for the interpretation of non-coding variants within the 5kb upstream and 5kb
untranslated/UTR of the clinically relevant transcript. After confirmation of variant location as

exclusively non-coding, and without potential splicing impact, variants would be annotated for location
within a promoter region using EPDnew, followed by scoring using CADD and/or REMM for variants
outside an EPDnew-defined promoter region. These annotations combined may be used individually
or combined to determine whether a computational code (PP3, BP4) may be applied for the variant.
Although LRs derived from this study indicate that specific categories may be used to provide moderate
evidence towards or against pathogenicity, we suggest a conservative approach would be to apply this
bioinformatic evidence at supporting level in the first instance. The justification for such a conservative
approach is that the variants identified as disease-causing to date may be biased towards those that
were prioritized for functional and clinical follow-up precisely because they lay in recognizable
promoter elements. Replication studies, using independent reference dataset variants, would be
helpful to assess if such caution is justified.

To reiterate the need to calibrate thresholds considering variant location and type, we refer to a recent
study calibrating tools for missense variant impact prediction, which reported that CADD scores $\geq$
25.3 provide supporting evidence towards pathogenicity (PP3) and CADD scores $\leq$22.7 provide
supporting evidence against pathogenicity (BP4) [28]. Our findings show clearly that these thresholds
are inappropriate for regulatory region variants; use of CADD <22.7 would incorrectly assign a benign
prediction code for the majority of reported disease variants located in a genuine cis-regulatory region
(93.5% in our final disease reference dataset). Calibration using our compiled cis-regulatory region
reference datasets determined that CADD score $\geq$ 10 provides moderate evidence towards
pathogenicity (LR 6.41), and score $\leq$8 or provides moderate evidence against pathogenicity (LR 0.22).
Only 6.88% of variants would be considered "no code applicable/undetermined". Additionally, a tiered
approach combining EPDnew promoter region location with CADD and/or REMM scores enabled
increased evidence strength (LR>10 rather than >6) for a proportion of variants, and fewer variants
with incorrectly designated evidence (7% all predictions combined, rather than >9% via all other
approaches). However, this approach comes with a compromise in terms of fewer variants assigned a
bioinformatic category (84% with all predictions combined rather than >90% with a single tool).

We stress that our study design has not provided tool calibration for regulatory region variants that
also overlap in location with a coding region, for which bioinformatic score thresholds are likely to be
different. Recognizing this limitation, our calibration study using carefully refined reference datasets
represents an important advance for use of bioinformatic prediction evidence in the clinical
classification of variants located exclusively within 5' cis-regulatory regions of Mendelian disease genes.

Figure 8. Recommended process for assigning computational evidence of predicted impact for cis-regulatory region variant classification.

The presented calibration metrics are specific for use in cis-regulatory region variants. We suggest that before applying the metrics the following be verified: the variant is definitely within the cis-regulatory region (5kb 5' to the transcription start site to the translation start site of the clinically relevant transcript); the variant is not also within a protein-coding region since thresholds defined here have not been validated for variants that overlap with any coding region; the variant is not predicted to impact splicing, a reasonably well predicted mechanism of variant impact likely to take molecular precedence over variant impact on gene regulation. When the variant is verified as a predicted cis-regulatory region variant, EPDnew overlap (location in a promoter region), CADD and REMM scores can be used to determine if the variant has predicted impact, no predicted impact, or if the impact remains undetermined (no evidence provided). Based on the categories as defined above, computational evidence can then be used to assign at least supporting evidence for computational ACMG/AMP code PP3 (predicted impact/towards pathogenicity) or BP4 (predicted no impact/against pathogenicity).

Appendices

601 None included.

Declaration of interests

603 The authors declare no competing interests.

Acknowledgments

605 We would like to thank Daffodil Canson and Jonathan Beesley for their advice throughout results
606 generation and manuscript preparation. RV, MM, ALD and ABS were supported by NHMRC Funding
607 (APP177524). The work of A.L.D. was also supported in part by National Institutes of Health grant R01
608 CA264971.

Author contributions

610 RMV, Conceptualization, Formal analysis, Methodology, Investigation, Visualization, Writing.
611 MM, Data curation, Formal analysis, Visualization, Writing.
612 ALD, Methodology, Writing, Software, Resources.
613 ABS, Conceptualization, Funding acquisition, Methodology, Writing, Supervision.
614

Web resources

616 Web-based resources and URLs are provided in Table S9.
617

Data and code availability

619 All information to replicate the findings of this study are available in the supplemental material. The
620 code and datasets generated during this study are available through github, at cisregulatoryV,
621 https://github.com/ReeVee2006/cisregulatoryV.

References

1. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-24.

2. Ellingford JM, Ahn JW, Bagnall RD, Baralle D, Barton S, Campbell C, et al. Recommendations for clinical interpretation of variants found in non-coding regions of the genome. Genome Med. 2022;14(1):73.

3. Smith M, Flodman PL. Expanded Insights Into Mechanisms of Gene Expression and Disease Related Disruptions. Front Mol Biosci. 2018;5:101.

4. Carninci P, Sandelin A, Lenhard B, Katayama S, Shimokawa K, Ponjavic J, et al. Genome-wide analysis of mammalian promoter architecture and evolution. Nat Genet. 2006;38(6):626-35.

5. Burke TW, Kadonaga JT. The downstream core promoter element, DPE, is conserved from Drosophila to humans and is recognized by TAFII60 of Drosophila. Genes Dev. 1997;11(22):3020-31.

6. Vo Ngoc L, Cassidy CJ, Huang CY, Duttke SH, Kadonaga JT. The human initiator is a distinct and abundant element that is precisely positioned in focused core promoters. Genes Dev. 2017;31(1):6-11.

7. Saxonov S, Berg P, Brutlag DL. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci U S A. 2006;103(5):1412-7.

8. Zambelli F, Pavesi G. Genome wide features, distribution and correlations of NF-Y binding sites. Biochim Biophys Acta Gene Regul Mech. 2017;1860(5):581-9.

9. Boyle AP, Davis S, Shulha HP, Meltzer P, Margulies EH, Weng Z, et al. High-resolution mapping and characterization of open chromatin across the genome. Cell. 2008;132(2):311-22.

10. Vavouri T, Lehner B. Human genes with CpG island promoters have a distinct transcription-associated chromatin organization. Genome Biol. 2012;13(11):R110.

11. Zoghbi HY, Beaudet AL. Epigenetics and Human Disease. Cold Spring Harb Perspect Biol. 2016;8(2):a019497.

12. Soto LF, Li Z, Santoso CS, Berenson A, Ho I, Shen VX, et al. Compendium of human transcription factor effector domains. Mol Cell. 2022;82(3):514-26.

13. Phornphutkul C, Anikster Y, Huizing M, Braun P, Brodie C, Chou JY, et al. The promoter of a lysosomal membrane transporter gene, CTNS, binds Sp-1, shares sequences with the promoter of an adjacent gene, CARKL, and causes cystinosis if mutated in a critical region. Am J Hum Genet. 2001;69(4):712-21.

14. Teresi RE, Zbuk KM, Pezzolesi MG, Waite KA, Eng C. Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation. Am J Hum Genet. 2007;81(4):756-67.

15. Savinkova L, Drachkova I, Arshinova T, Ponomarenko P, Ponomarenko M, Kolchanov N. An experimental verification of the predicted effects of promoter TATA-box polymorphisms associated with human diseases on interactions between the TATA boxes and TATA-binding protein. PLoS One. 2013;8(2):e54626.

16. Lin Y, Lin S, Baxter MD, Lin L, Kennedy SM, Zhang Z, et al. Novel APC promoter and exon 1B deletion and allelic silencing in three mutation-negative classic familial adenomatous polyposis families. Genome Med. 2015;7(1):42.

17. Hesson LB, Packham D, Kwok CT, Nunez AC, Ng B, Schmidt C, et al. Lynch syndrome associated with two MLH1 promoter variants and allelic imbalance of MLH1 expression. Hum Mutat. 2015;36(6):622-30.

18. Pabinger S, Dander A, Fischer M, Snajder R, Sperk M, Efremova M, et al. A survey of tools for variant analysis of next-generation genome sequencing data. Brief Bioinform. 2014;15(2):256-78.

19. Drubay D, Gautheret D, Michiels S. A benchmark study of scoring methods for non-coding mutations. Bioinformatics. 2018;34(10):1635-41.

20.   Biggs H, Parthasarathy P, Gavryushkina A, Gardner PP. ncVarDB: a manually curated database
for pathogenic non-coding variants and benign controls. Database (Oxford). 2020;2020.

21.   Gloss BS, Dinger ME. Realizing the significance of noncoding functionality in clinical
genomics. Exp Mol Med. 2018;50(8):1-8.

22.   Rojano E, Seoane P, Ranea JAG, Perkins JR. Regulatory variants: from detection to predicting
impact. Brief Bioinform. 2019;20(5):1639-54.

23.   Kuksa PP, Greenfest-Allen E, Cifello J, Ionita M, Wang H, Nicaretta H, et al. Scalable
approaches for functional analyses of whole-genome sequencing non-coding variants. Hum Mol
Genet. 2022;31(R1):R62-R72.

24.   Wang Z, Zhao G, Li B, Fang Z, Chen Q, Wang X, et al. Performance comparison of
computational methods for the prediction of the function and pathogenicity of non-coding variants.
Genomics Proteomics Bioinformatics. 2022.

25.   Tabarini N, Biagi E, Uva P, Iovino E, Pippucci T, Seri M, et al. Exploration of Tools for the
Interpretation of Human Non-Coding Variants. Int J Mol Sci. 2022;23(21).

26.   Wilcox EH, Sarmady M, Wulf B, Wright MW, Rehm HL, Biesecker LG, et al. Evaluating the
impact of in silico predictors on clinical variant classification. Genet Med. 2022;24(4):924-30.

27.   Tavtigian SV, Greenblatt MS, Harrison SM, Nussbaum RL, Prabhu SA, Boucher KM, et al.
Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework.
Genet Med. 2018;20(9):1054-60.

28.   Pejaver V, Byrne AB, Feng BJ, Pagel KA, Mooney SD, Karchin R, et al. Calibration of
computational tools for missense variant pathogenicity classification and ClinGen recommendations
for PP3/BP4 criteria. Am J Hum Genet. 2022;109(12):2163-77.

29.   Davydov EV, Goode DL, Sirota M, Cooper GM, Sidow A, Batzoglou S. Identifying a high
fraction of the human genome to be under selective constraint using GERP++. PLoS Comput Biol.
2010;6(12):e1001025.

30.   Pollard KS, Hubisz MJ, Rosenbloom KR, Siepel A. Detection of nonneutral substitution rates
on mammalian phylogenies. Genome Res. 2010;20(1):110-21.

31.   Rentzsch P, Schubach M, Shendure J, Kircher M. CADD-Splice-improving genome-wide variant
effect prediction using deep learning-derived splice scores. Genome Med. 2021;13(1):31.

32.   Feng BJ. PERCH: A Unified Framework for Disease Gene Prioritization. Hum Mutat.
2017;38(3):243-51.

33.   Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving
access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46(D1):D1062-D7.

34.   Caron B, Luo Y, Rausell A. NCBoost classifies pathogenic non-coding variants in Mendelian
diseases through supervised learning on purifying selection signals in humans. Genome Biol.
2019;20(1):32.

35.   Smedley D, Schubach M, Jacobsen JOB, Kohler S, Zemojtel T, Spielmann M, et al. A Whole-
Genome Analysis Framework for Effective Identification of Pathogenic Regulatory Variants in
Mendelian Disease. Am J Hum Genet. 2016;99(3):595-606.

36.   Davidson AL, Kondrashova O, Leonard C, Wood S, Tudini E, Hollway GE, et al. Analysis of
hereditary cancer gene variant classifications from ClinVar indicates a need for regular reassessment
of clinical assertions. Hum Mutat. 2022;43(12):2054-62.

37.   Smedley D, Haider S, Ballester B, Holland R, London D, Thorisson G, et al. BioMart--biological
queries made easy. BMC Genomics. 2009;10:22.

38.   Niu YN, Roberts EG, Denisko D, Hoffman MM. Assessing and assuring interoperability of a
genomics file format. Bioinformatics. 2022;38(13):3327-36.

39.   Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, et al. A genome-wide
mutational constraint map quantified from variation in 76,156 human genomes. bioRxiv.
2022:2022.03.20.485034.

40.   Alsheikh AJ, Wollenhaupt S, King EA, Reeb J, Ghosh S, Stolzenburg LR, et al. The landscape of
GWAS validation; systematic review identifying 309 validated non-coding variants across 130 human
diseases. BMC Med Genomics. 2022;15(1):74.
41.   Dreos R, Ambrosini G, Groux R, Cavin Perier R, Bucher P. The eukaryotic promoter database
in its 30th year: focus on non-vertebrate organisms. Nucleic Acids Res. 2017;45(D1):D51-D5.
42.   McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The Ensembl Variant Effect
Predictor. Genome Biol. 2016;17(1):122.
43.   Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, Darbandi SF, Knowles D, Li YI, et
al. Predicting Splicing from Primary Sequence with Deep Learning. Cell. 2019;176(3):535-48 e24.
44.   Walker LC, Hoya M, Wiggins GAR, Lindy A, Vincent LM, Parsons MT, et al. Using the
ACMG/AMP framework to capture evidence related to predicted and observed impact on splicing:
Recommendations from the ClinGen SVI Splicing Subgroup. Am J Hum Genet. 2023;110(7):1046-67.
45.   Parsons MT, Tudini E, Li H, Hahnen E, Wappenschmidt B, Feliubadalo L, et al. Large scale
multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to
support clinical variant classification. Hum Mutat. 2019;40(9):1557-78.
46.   Davidson AL, Leonard C, Koufariotis LT, Parsons MT, Hollway GE, Pearson JV, et al.
Considerations for using population frequency data in germline variant interpretation: Cancer
syndrome genes as a model. Hum Mutat. 2021;42(5):530-6.
47.   Shihab HA, Rogers MF, Gough J, Mort M, Cooper DN, Day IN, et al. An integrative approach to
predicting the functional effects of non-coding and coding sequence variation. Bioinformatics.
2015;31(10):1536-43.
48.   Rogers MF, Shihab HA, Mort M, Cooper DN, Gaunt TR, Campbell C. FATHMM-XF: accurate
prediction of pathogenic point mutations via extended features. Bioinformatics. 2018;34(3):511-3.
49.   Ionita-Laza I, McCallum K, Xu B, Buxbaum JD. A spectral approach integrating functional
genomic annotations for coding and noncoding variants. Nat Genet. 2016;48(2):214-20.
50.   Huang YF, Gulko B, Siepel A. Fast, scalable prediction of deleterious noncoding variants from
functional and population genomic data. Nat Genet. 2017;49(4):618-24.
51.   Zerbino DR, Wilder SP, Johnson N, Juettemann T, Flicek PR. The ensembl regulatory build.
Genome Biol. 2015;16(1):56.